Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Laboratory for Translational Chemistry and Drug Discovery, Department of Chemistry, Hansraj College, University of Delhi, Delhi, India.
J Biomol Struct Dyn. 2023;41(24):15053-15066. doi: 10.1080/07391102.2023.2186710. Epub 2023 Mar 11.
Matrix Metalloproteinases-9 (MMP-9) is one of the important targets that play a vital role in various diseases such as cancer, Alzheimer's, arthritis, etc. Traditionally, MMP-9 inhibitors have been unable to achieve selectivity to get around this target; thereby, novel mechanisms such as inhibition of activated MMP-9 zymogen (pro-MMP-9) have been discovered. The JNJ0966 was one of the few compounds that attained the requisite selectivity by inhibiting the activation of MMP-9 zymogen (pro-MMP-9). Since JNJ0966, no other small molecules have been identified. Herein, extensive studies were called upon to bolster the prospect of exploring potential candidates. The key objective of this research is to identify the potential hits from the ChEMBL database molecular docking and dynamics approach. Protein with PDB ID: 5UE4, having a unique inhibitor in an allosteric binding pocket of MMP-9, was chosen for the study. Structure-based virtual screening and MMGBSA binding affinity calculations were performed, and five potential hits were finalized. Detailed analysis of the best-scoring molecules was performed with ADMET analysis and molecular dynamics (MD) simulation. All five hits outperformed JNJ0966 in the docking assessment, ADMET analysis, and molecular dynamics simulation. Accordingly, our research findings imply that these hits can be investigated for and studies against proMMP9 and might be explored as potential anticancer drugs. The outcome of our research might contribute in expediting the exploration of drugs that inhibits proMMP-9.Communicated by Ramaswamy H. Sarma.
基质金属蛋白酶-9(MMP-9)是在癌症、阿尔茨海默病、关节炎等各种疾病中发挥重要作用的重要靶点之一。传统上,MMP-9 抑制剂无法实现选择性以绕过该靶点;因此,发现了新的机制,如抑制激活的 MMP-9 酶原(pro-MMP-9)。JNJ0966 是少数通过抑制 MMP-9 酶原(pro-MMP-9)的激活而获得所需选择性的化合物之一。自 JNJ0966 以来,尚未发现其他小分子。在此,广泛的研究被呼吁以支持探索潜在候选药物的前景。本研究的主要目标是从 ChEMBL 数据库中确定潜在的命中物,采用分子对接和动力学方法。选择具有独特抑制剂的 PDB ID:5UE4 蛋白作为研究对象。进行了基于结构的虚拟筛选和 MMGBSA 结合亲和力计算,并最终确定了五个潜在的命中物。通过 ADMET 分析和分子动力学(MD)模拟对得分最高的分子进行了详细分析。在对接评估、ADMET 分析和分子动力学模拟中,所有五个命中物都优于 JNJ0966。因此,我们的研究结果表明,这些命中物可以针对 proMMP9 进行和研究,并可能作为潜在的抗癌药物进行探索。我们研究的结果可能有助于加速抑制 proMMP-9 的药物的探索。